Similarly, in prostate cancer, it was reported that both SUMO1 and AR interactions (in IRC117539, which is a new molecule that targets AR for proteasomal degradation, untreated and treated cells) and SUMO2/3 and AR interactions (in IRC117539 treated cells) were largely nuclear in LNCaP cells using PLA (Auvin et al. 2019). Here, AR is linked to prostate cancer.